The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
Ind-Ra maintains a neutral outlook for healthcare in FY23
Key takeaways of Q3FY22 quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Subscribe To Our Newsletter & Stay Updated
